| Symbol | CGEM |
|---|---|
| Name | CULLINAN THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | ONE MAIN STREET,SUITE 520, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 617 410-4650 |
| Fax | — |
| — | |
| Website | https://cullinantherapeutics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001789972 |
| Description | Cullinan Therapeutics, Inc., formerly Cullinan Oncology, Inc., is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. It has a portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its pipeline includes CLN-619, CLN-978, Zipalertinib (CLN-081/TAS6417), CLN-049, CLN-418, and CLN-617. Its lead unpartnered program, CLN-619, is a humanized lgG1 monoclonal antibody (mAb) that binds to the stress induced ligands MICA and MICB (MICA/B), which are expressed on a variety of solid tumors and hematologic malignancies. CLN-978 is a novel, highly potent, half-life extended CD19xCD3 bispecific T cell engager construct. CLN-081/TAS6417 is a novel, orally available, covalent inhibitor of mutant epidermal growth factor receptor (EGFR). CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-418 is a B7H4 x 4-1BB bispecific immune activator. Additional info from NASDAQ: |
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
Read moreMichaelson Jennifer 🟡 adjusted position in 8.0K shares (1 derivative) of Cullinan Therapeutics, Inc. (CGEM) at $17.82 Transaction Date: Jul 06, 2026 | Filing ID: 297605
Read more📋 JENNIFER MICHAELSON (Officer) plans to sell 8K shares of CULLINAN THERAPEUTICS, INC. (at $17.63 each, total $141K) Filed: Jul 06, 2026 | ID: 006865
Read moreSUMER JACQUELYN L 🟢 acquired 2.5K shares of Cullinan Therapeutics, Inc. (CGEM) at $8.60 Transaction Date: Jun 30, 2026 | Filing ID: 294869
Read moreFenton Mary Kay 🟢 acquired 1.5K shares of Cullinan Therapeutics, Inc. (CGEM) at $8.60 Transaction Date: Jun 30, 2026 | Filing ID: 294863
Read more(99% Neutral) CULLINAN THERAPEUTICS, INC. (CGEM) Announces Regulatory Update
Read more(90% Positive) CULLINAN THERAPEUTICS, INC. (CGEM) Announces Enrollment Update for data Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read moreCullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress
Read moreCullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
Read more(90% Positive) CULLINAN THERAPEUTICS, INC. (CGEM) Announces Enrollment Update for depletion Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07722767 | A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in A… | Phase1 | AML (Acute Myeloid Leukemia) | Not_Yet_Recruiting | 2026-10-15 | 2030-08-31 | ClinicalTrials.gov |
| NCT07041099 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager,… | Phase1 | Sjögren | Recruiting | 2025-10-01 | 2029-03-15 | ClinicalTrials.gov |
| NCT06994143 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager,… | Phase1 | Rheumatoid Arthritis (RA | Recruiting | 2025-05-19 | 2028-12-30 | ClinicalTrials.gov |
| NCT06613360 | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager,… | Phase1 | SLE | Recruiting | 2025-01-21 | 2027-12-01 | ClinicalTrials.gov |
| NCT06381141 | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refr… | Phase1 | Multiple Myeloma | Active_Not_Recruiting | 2024-09-03 | 2027-03-01 | ClinicalTrials.gov |
| NCT06035744 | CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced S… | Phase1 | Advanced Solid Tumor | Terminated | 2023-12-12 | 2026-06-16 | ClinicalTrials.gov |
| NCT05879744 | A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hod… | Phase1 | NHL | Active_Not_Recruiting | 2023-05-31 | 2027-04-01 | ClinicalTrials.gov |
| NCT05143996 | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or My… | Phase1 | Relapsed/Refractory Acute Myeloid Leukemia (AML) | Recruiting | 2021-11-18 | 2027-06-01 | ClinicalTrials.gov |
| NCT05117476 | A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Soli… | Phase1 | Advanced Solid Tumor | Active_Not_Recruiting | 2021-10-29 | 2026-06-01 | ClinicalTrials.gov |
| NCT04036682 | A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer | Phase1 | Non Small Cell Lung Cancer | Active_Not_Recruiting | 2019-10-31 | 2028-03-31 | ClinicalTrials.gov |
| NCT03682055 | Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive … | Phase1 | Nasopharyngeal Carcinoma | Terminated | 2019-04-04 | 2020-08-08 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Venetoclax | Other | Phase PHASE1 | AML (Acute Myeloid Leukemia) | NOT_YET_RECRUITING | NCT07722767 |
| Azacitidine | Other | Phase PHASE1 | AML (Acute Myeloid Leukemia) | NOT_YET_RECRUITING | NCT07722767 |
| CLN-049 | Other | Phase PHASE1 | AML (Acute Myeloid Leukemia) | NOT_YET_RECRUITING | NCT07722767 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT06035744 |
| CLN-617 | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT06035744 |
| CLN-081 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04036682 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-978 | Other | Phase PHASE1 | Rheumatoid Arthritis (RA | RECRUITING | NCT06994143 |
| CLN-978 | Other | Phase PHASE1 | Rheumatoid Arthritis (RA | RECRUITING | NCT06994143 |
| CLN-978 | Other | Phase PHASE1 | Rheumatoid Arthritis (RA | RECRUITING | NCT06994143 |
| CLN-978 | Other | Phase PHASE1 | Rheumatoid Arthritis (RA | RECRUITING | NCT06994143 |
| CLN-978 | Other | Phase PHASE1 | Rheumatoid Arthritis (RA | RECRUITING | NCT06994143 |
| CLN-978 | Other | Phase PHASE1 | Rheumatoid Arthritis (RA | RECRUITING | NCT06994143 |
| CLN-978 | Other | Phase PHASE1 | Rheumatoid Arthritis (RA | RECRUITING | NCT06994143 |
| CLN-978 | Other | Phase PHASE1 | Rheumatoid Arthritis (RA | RECRUITING | NCT06994143 |
| VK-2019 | Other | Phase PHASE1 | Nasopharyngeal Carcinoma | TERMINATED | NCT03682055 |
| CLN-978 | Other | Phase PHASE1 | NHL | ACTIVE_NOT_RECRUITING | NCT05879744 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06035744 |
| CLN-617 | Other | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06035744 |
| CLN-081 | Other | Phase PHASE1 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04036682 |
| CLN-978 | Other | Phase PHASE1 | Rheumatoid Arthritis (RA | RECRUITING | NCT06994143 |
| CLN-619 | Other | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT06381141 |
| CLN-978 | Other | Phase PHASE1 | Sjögren | RECRUITING | NCT07041099 |
| Datopotamab deruxtecan-dlnk (Dato-DXd) | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| pemetrexed | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| Carboplatin AUC 6 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| Paclitaxel | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| Pembrolizumab | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| CLN-619 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| CLN-049 | Other | Phase PHASE1 | Relapsed/Refractory Acute Myeloid Leukemia (AML) | RECRUITING | NCT05143996 |
| CLN-978 | Other | Phase PHASE1 | SLE | RECRUITING | NCT06613360 |
| CLN-617 | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06035744 |
| CLN-978 | DRUG | Phase PHASE1 | Sjögren | RECRUITING | NCT07041099 |
| CLN-049 | DRUG | Phase PHASE1 | Relapsed/Refractory Acute Myeloid Leukemia (AML) | RECRUITING | NCT05143996 |
| Datopotamab deruxtecan-dlnk (Dato-DXd) | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| pemetrexed | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| Carboplatin AUC 6 | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| Paclitaxel | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05117476 |
| Pembrolizumab | DRUG | Phase PHASE1 | Advanced Solid Tumor | RECRUITING | NCT06035744 |
| CLN-619 | DRUG | Phase PHASE1 | Multiple Myeloma | ACTIVE_NOT_RECRUITING | NCT06381141 |
| CLN-081 | DRUG | Phase PHASE1 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04036682 |
| VK-2019 | DRUG | Phase PHASE1 | Nasopharyngeal Carcinoma | TERMINATED | NCT03682055 |